IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (...
IO Biotech, Inc. (IOBT)
Company Research
Source: GlobeNewswire
Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs)Pre-clinical data for IO Biotech’s additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-ß, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasisData presented at the Society for Immunotherapy of Cancer’s Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced new pre-clinical data for IO Biotech’s next vaccine candidate, IO112, and additional candidate, IO170, will be presented at the Society for Immunotherapy of Cancer’s 40th Annual Mee
Show less
Read more
Impact Snapshot
Event Time:
IOBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOBT alerts
High impacting IO Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
IOBT
News
- IO Biotech Announces Participation in Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- IO Biotech Announces Participation in Upcoming December Investor ConferencesGlobeNewswire
- IO Biotech (NASDAQ:IOBT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IOBT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- IO Biotech GAAP EPS of -$0.13 beats by $0.25 [Seeking Alpha]Seeking Alpha
IOBT
Sec Filings
- 11/21/25 - Form 8-K
- 11/18/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- IOBT's page on the SEC website